A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.

<h4>Background</h4>The E7 protein of the Human Papillomavirus (HPV) type 16, being involved in malignant cellular transformation, represents a key antigen for developing therapeutic vaccines against HPV-related lesions and cancers. Recombinant production of this vaccine antigen in an act...

Full description

Bibliographic Details
Main Authors: Olivia C Demurtas, Silvia Massa, Paola Ferrante, Aldo Venuti, Rosella Franconi, Giovanni Giuliano
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23626690/pdf/?tool=EBI
_version_ 1828897726598742016
author Olivia C Demurtas
Silvia Massa
Paola Ferrante
Aldo Venuti
Rosella Franconi
Giovanni Giuliano
author_facet Olivia C Demurtas
Silvia Massa
Paola Ferrante
Aldo Venuti
Rosella Franconi
Giovanni Giuliano
author_sort Olivia C Demurtas
collection DOAJ
description <h4>Background</h4>The E7 protein of the Human Papillomavirus (HPV) type 16, being involved in malignant cellular transformation, represents a key antigen for developing therapeutic vaccines against HPV-related lesions and cancers. Recombinant production of this vaccine antigen in an active form and in compliance with good manufacturing practices (GMP) plays a crucial role for developing effective vaccines. E7-based therapeutic vaccines produced in plants have been shown to be active in tumor regression and protection in pre-clinical models. However, some drawbacks of in whole-plant vaccine production encouraged us to explore the production of the E7-based therapeutic vaccine in Chlamydomonas reinhardtii, an organism easy to grow and transform and fully amenable to GMP guidelines.<h4>Methodology/principal findings</h4>An expression cassette encoding E7GGG, a mutated, attenuated form of the E7 oncoprotein, alone or as a fusion with affinity tags (His6 or FLAG), under the control of the C. reinhardtii chloroplast psbD 5' UTR and the psbA 3' UTR, was introduced into the C. reinhardtii chloroplast genome by homologous recombination. The protein was mostly soluble and reached 0.12% of total soluble proteins. Affinity purification was optimized and performed for both tagged forms. Induction of specific anti-E7 IgGs and E7-specific T-cell proliferation were detected in C57BL/6 mice vaccinated with total Chlamydomonas extract and with affinity-purified protein. High levels of tumor protection were achieved after challenge with a tumor cell line expressing the E7 protein.<h4>Conclusions</h4>The C. reinhardtii chloroplast is a suitable expression system for the production of the E7GGG protein, in a soluble, immunogenic form. The production in contained and sterile conditions highlights the potential of microalgae as alternative platforms for the production of vaccines for human uses.
first_indexed 2024-12-13T15:02:58Z
format Article
id doaj.art-0963fa34853949e3bb62bab97b1d3536
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-13T15:02:58Z
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-0963fa34853949e3bb62bab97b1d35362022-12-21T23:41:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0184e6147310.1371/journal.pone.0061473A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.Olivia C DemurtasSilvia MassaPaola FerranteAldo VenutiRosella FranconiGiovanni Giuliano<h4>Background</h4>The E7 protein of the Human Papillomavirus (HPV) type 16, being involved in malignant cellular transformation, represents a key antigen for developing therapeutic vaccines against HPV-related lesions and cancers. Recombinant production of this vaccine antigen in an active form and in compliance with good manufacturing practices (GMP) plays a crucial role for developing effective vaccines. E7-based therapeutic vaccines produced in plants have been shown to be active in tumor regression and protection in pre-clinical models. However, some drawbacks of in whole-plant vaccine production encouraged us to explore the production of the E7-based therapeutic vaccine in Chlamydomonas reinhardtii, an organism easy to grow and transform and fully amenable to GMP guidelines.<h4>Methodology/principal findings</h4>An expression cassette encoding E7GGG, a mutated, attenuated form of the E7 oncoprotein, alone or as a fusion with affinity tags (His6 or FLAG), under the control of the C. reinhardtii chloroplast psbD 5' UTR and the psbA 3' UTR, was introduced into the C. reinhardtii chloroplast genome by homologous recombination. The protein was mostly soluble and reached 0.12% of total soluble proteins. Affinity purification was optimized and performed for both tagged forms. Induction of specific anti-E7 IgGs and E7-specific T-cell proliferation were detected in C57BL/6 mice vaccinated with total Chlamydomonas extract and with affinity-purified protein. High levels of tumor protection were achieved after challenge with a tumor cell line expressing the E7 protein.<h4>Conclusions</h4>The C. reinhardtii chloroplast is a suitable expression system for the production of the E7GGG protein, in a soluble, immunogenic form. The production in contained and sterile conditions highlights the potential of microalgae as alternative platforms for the production of vaccines for human uses.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23626690/pdf/?tool=EBI
spellingShingle Olivia C Demurtas
Silvia Massa
Paola Ferrante
Aldo Venuti
Rosella Franconi
Giovanni Giuliano
A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
PLoS ONE
title A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
title_full A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
title_fullStr A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
title_full_unstemmed A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
title_short A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
title_sort chlamydomonas derived human papillomavirus 16 e7 vaccine induces specific tumor protection
url https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23626690/pdf/?tool=EBI
work_keys_str_mv AT oliviacdemurtas achlamydomonasderivedhumanpapillomavirus16e7vaccineinducesspecifictumorprotection
AT silviamassa achlamydomonasderivedhumanpapillomavirus16e7vaccineinducesspecifictumorprotection
AT paolaferrante achlamydomonasderivedhumanpapillomavirus16e7vaccineinducesspecifictumorprotection
AT aldovenuti achlamydomonasderivedhumanpapillomavirus16e7vaccineinducesspecifictumorprotection
AT rosellafranconi achlamydomonasderivedhumanpapillomavirus16e7vaccineinducesspecifictumorprotection
AT giovannigiuliano achlamydomonasderivedhumanpapillomavirus16e7vaccineinducesspecifictumorprotection
AT oliviacdemurtas chlamydomonasderivedhumanpapillomavirus16e7vaccineinducesspecifictumorprotection
AT silviamassa chlamydomonasderivedhumanpapillomavirus16e7vaccineinducesspecifictumorprotection
AT paolaferrante chlamydomonasderivedhumanpapillomavirus16e7vaccineinducesspecifictumorprotection
AT aldovenuti chlamydomonasderivedhumanpapillomavirus16e7vaccineinducesspecifictumorprotection
AT rosellafranconi chlamydomonasderivedhumanpapillomavirus16e7vaccineinducesspecifictumorprotection
AT giovannigiuliano chlamydomonasderivedhumanpapillomavirus16e7vaccineinducesspecifictumorprotection